Stocktoria
FENNEC PHARMACEUTICALS INC. FENC
FENNEC PHARMACEUTICALS INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.6M | $47.5M | $23.8M | $1.8M | — | $200,000 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | $20.0M | $1.4M | — | — | — | — | — | — |
| R&D expense | $250,000 | $307,000 | $56,000 | $3.5M | $5.0M | $5.1M | $5.6M | $5.0M | $1.9M | $472,000 |
| Operating income | -$6.3M | $2.6M | -$12.8M | -$22.6M | -$17.2M | -$17.9M | -$13.0M | -$10.4M | -$7.0M | -$2.9M |
| Income tax | $106,000 | $365,000 | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$9.7M | -$436,000 | -$16.0M | -$23.7M | -$17.3M | -$18.1M | -$12.8M | -$9.9M | -$7.0M | -$2.8M |
| EPS (diluted) | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.67 | $-0.76 | — | — | — | — |
| Operating cash flow | -$12.5M | $27.0M | -$17.1M | -$18.1M | -$14.2M | -$15.6M | -$9.1M | -$7.8M | -$3.6M | -$2.1M |
| Cash & equivalents | $36.8M | $26.6M | $13.3M | $23.8M | $21.1M | $30.3M | $13.7M | $22.8M | $28.3M | $3.9M |
| Total assets | $70.6M | $44.9M | $26.9M | $26.9M | $22.4M | $31.4M | $14.1M | $22.9M | $28.4M | $4.0M |
| Total liabilities | $35.1M | $50.8M | $38.5M | $29.5M | $6.6M | $2.3M | $2.3M | $1.6M | $1.6M | $402,000 |
| Shareholders' equity | $35.5M | -$5.9M | -$11.6M | -$2.6M | $15.8M | $29.1M | $11.9M | $21.3M | $26.8M | $3.6M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -6.1% | +99.9% | +1244.4% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.